NASDAQ: ABUS Maintains High Stock Value: Is It The Right Time To Buy?

The Biopharmaceutical Company NASDAQ: ABUS at mainly focuses on the development and commercialization of a cure treatment for chronic Hepatitis B Virus infected patients in Canada and the U.S. The company also develops RNAi drugs and AB-729 (a second-generation RNAi) for hepatitis affected patients. Arbutus Biopharma Corporation share price went straight up by 6.35% from the previous closing price. You can compare it with its previous year high value which is $3.66. While ABUS stocks collected almost +8.06% of gains in the last trading sessions, many investors are now interested to buy ABUS shares.

NASDAQ: ABUS current market performance:

ABUS’s stock was trading at $2.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then its stock value decreased by 7.0% and is trading now at $2.40(as of 18th July 2020). This organization earned $1.49 million during the quarter, compared to the consensus estimate of $1.81million. ABUS reported earnings per share (EPS) for the quarter is $0.25 beating the Zacks’ consensus estimate of ($0.31) Next earning date is scheduled to release on Monday, August 3rd, 2020.

NASDAQ: ABUS has a market capitalization of $165.50 million and generates $6.01 million in revenue each year. As of the most recent Fiscal, the EPS (earnings per share) of ABUS is $1.62 and Net income (Profit) is $153.72 million. Research analysts have issued 1-year price targets which range from $4.00 to $10.00. On average, they expect the share price to reach $5.80 in the next year which suggests an increase of 141.7%from the stock current price. Its Forward P/E ratio is -2.82 and Price per sales (last 12 months) is 24.26.

Is Arbutus Biopharma Corporation worth an investment?

Last week, ABUS stocks went up 8.06% with one month’s jump of 1.52%. The quarterly performance of ABUS resulted in 67.50% while the annual performance rate was -0.99%. If you will calculate the simple moving average of the last 20 days, the result will be 5.26% of ABUS stocks had a simple moving average of 1.96%.

The 36 months’ beta value for NASDAQ: ABUS stocks is at 2.84. It indicates the measure of the systematic risk of a security in comparison to the market as a whole. Because of that, many analysts and investors are choosing to buy Arbutus Biopharma Corporation stocks now. The average price is $5.80 which is $2.01 lower than the current price. Plus, ABUS has a short float rate of 1.44% currently with a public float value of 44.46 Million and 1.16M average shares trading volume. Whether it is going to be a worthy investment to make; only the time can tell! You can check more information at stock trading platform. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.